Legend Biotech Corp Increase Decrease Through Share-based Payment Transactions
Legend Biotech Corp (LEGN) reported Increase Decrease Through Share-based Payment Transactions of $64.60 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions · last filed 2026-03-10
- Legend Biotech Corp increase decrease through share-based payment transactions for the quarter ending 2025-12-31 was $14.94M, a 11.95% increase year-over-year.
- Legend Biotech Corp increase decrease through share-based payment transactions for the quarter ending 2025-09-30 was $15.02M, a 0.64% decline year-over-year.
- Legend Biotech Corp increase decrease through share-based payment transactions for the quarter ending 2025-06-30 was $18.70M, a 13.99% decline year-over-year.
- Legend Biotech Corp increase decrease through share-based payment transactions for the quarter ending 2025-03-31 was $15.95M, a 14.74% decline year-over-year.
| Period end | Increase Decrease Through Share-based Payment Transactions 3 month | Increase Decrease Through Share-based Payment Transactions 6 month | Increase Decrease Through Share-based Payment Transactions 9 month | Increase Decrease Through Share-based Payment Transactions 12 month | Increase Decrease Through Share-based Payment Transactions 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $14.94M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $29.96M derived: sum of 2 quarters · filed 2026-03-10 | $48.65M derived: sum of 3 quarters · filed 2026-03-10 | $64.60M 20-F · filed 2026-03-10 | |
| 2025-09-30 | $15.02M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $33.71M derived: sum of 2 quarters · filed 2025-11-12 | $49.66M 6-K · filed 2025-11-12 | $63.01M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | $18.70M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $34.64M 6-K · filed 2025-08-11 | $47.99M derived: sum of 3 quarters · filed 2026-03-10 | $63.10M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $15.95M 6-K · filed 2025-05-13 | $29.29M derived: sum of 2 quarters · filed 2026-03-10 | $44.40M derived: sum of 3 quarters · filed 2026-03-10 | $66.14M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | $13.35M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $28.46M derived: sum of 2 quarters · filed 2026-03-10 | $50.20M derived: sum of 3 quarters · filed 2026-03-10 | $68.90M 20-F · filed 2026-03-10 | $68.94M 20-F · filed 2025-03-11 |
| 2024-09-30 | $15.11M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $36.85M derived: sum of 2 quarters · filed 2025-11-12 | $55.55M 6-K · filed 2025-11-12 | $68.16M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | $21.74M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $40.44M 6-K · filed 2025-08-11 | $53.05M derived: sum of 3 quarters · filed 2026-03-10 | $65.43M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | $18.70M 6-K · filed 2025-05-13 | $31.31M derived: sum of 2 quarters · filed 2026-03-10 | $43.69M derived: sum of 3 quarters · filed 2026-03-10 | $59.33M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | $12.61M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $24.99M derived: sum of 2 quarters · filed 2026-03-10 | $40.63M derived: sum of 3 quarters · filed 2026-03-10 | $47.70M 20-F · filed 2026-03-10 | $47.68M 20-F · filed 2024-03-19 |
| 2023-09-30 | $12.38M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $28.02M derived: sum of 2 quarters · filed 2024-11-12 | $35.09M 6-K · filed 2024-11-12 | $44.06M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $15.64M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $22.71M 6-K · filed 2024-08-09 | $31.69M derived: sum of 3 quarters · filed 2025-03-11 | $41.93M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $7.07M 6-K · filed 2024-05-13 | $16.04M derived: sum of 2 quarters · filed 2025-03-11 | $26.28M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $8.97M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $19.21M derived: sum of 2 quarters · filed 2025-03-11 | $34.34M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $10.24M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $25.36M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $15.13M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $20.16M 20-F · filed 2024-03-19 | ||||
| 2021-06-30 | $8.03M 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | $4.76M 20-F · filed 2023-03-30 | ||||
| 2020-06-30 | $668.00K 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | $1.27M 20-F/A · filed 2023-02-17 | ||||
| 2018-12-31 | $704.00K 20-F · filed 2021-04-02 |